🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changzhou
Clinical trial register · China

Clinical Trials in Changzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 66 Guangzhou 60 Chengdu 55 Hangzhou 41 Chongqing 38
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC20 Eli Lilly and Company12 AstraZeneca12 The First People's Hospital of Changzhou5 The First Affiliated Hospital with Nanjing Medical University5 Clear sponsor filter
Site location
Beijing66 Guangzhou60 Chengdu55 Hangzhou41 Chongqing38
All 63 locations
Target enrolment
to

Trials with a site in Changzhou

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
644
Beijing, Changzhou, Chongqing, Guangzhou, Huai'an, Ningbo, Shijiazhuang, Zhuzhou
2026-05-23
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843Crohn Disease
Janssen Research & Development, LLC
Phase 3
460
Beijing, Changzhou, Chongqing, Guangzhou, Hangzhou, Huai'an, Ningbo, Zhuzhou
2026-05-22
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
Janssen Research & Development, LLC
Phase 3
530
Changzhou, Chongqing, Guangzhou, Nanjing, Wuhan
2026-04-21
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai
2026-01-15
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
Janssen Research & Development, LLC
Phase 2/3
1,092
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou
2025-10-03
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
882
Beijing, Changzhou, Cheng Du Shi, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou
2025-10-01
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
Janssen Research & Development, LLC
Phase 3
655
Beijing, Changsha, Changzhou, Chengdu, Dazhou, Ganzhou, Guangzhou, Guiyang
2024-12-04
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Janssen Research & Development, LLC
Phase 3
196
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang
2024-10-29
Active, closed
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 2
305
Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing
2024-02-16
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
838
Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot
2024-01-22
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou
2022-10-25
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Haikou
2022-07-22
Active, closed
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049Crohn Disease
Janssen Research & Development, LLC
Phase 3
350
Bengbu, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Ganzhou
2022-01-19
Active, closed
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
1,054
Baoding, Baotou, Beijing, Bengbu, Changchun, Changzhou, Chengdu, Chongqing
2021-06-17
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
308
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou
2020-10-13
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
1,074
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-09-30
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
Janssen Research & Development, LLC
Phase 2/3
1,409
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2018-04-13
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/changzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Changzhou that also match the filters currently applied.

How many clinical trials are recruiting in Changzhou?

8 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changzhou), 20 studies
PhaseStudiesRecruitingShare
Phase 315675%
Phase 23115%
Phase 2/32110%

Most active sponsors

Lead sponsors with the most studies (Changzhou)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC208
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.